Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program

ObjectivesAs of 2019, quadrivalent influenza vaccine (QIV) has replaced trivalent (TIV) in the national immunization program The Netherlands. Target groups are individuals 60+ years age and those with chronic diseases. objective was to estimate incremental break-even price QIV over TIV at a threshold €20 000 per quality-adjusted life-year (QALY).MethodsAn age-structured compartmental dynamic model adapted for Netherlands assess health outcomes associated costs vaccinating all higher risk instead seasons 2010 2018. Influenza incidence rates were derived from global database. Other parameters (probabilities, QALYs costs) extracted literature applied according Dutch guidelines. A QALY prices versus TIV. Sensitivity analyses performed test robustness outcomes.ResultsRetrospectively, vaccination could have prevented on average 9500 symptomatic cases, 2130 outpatient visits, 84 hospitalizations, 38 deaths year This translates into 385 398 life-years potentially gained. On average, totals €431 527 direct €2 388 810 indirect been saved each year.ConclusionUsing during 2018 would cost-effective an maximally €3.81 (95% confidence interval, €3.26-4.31). analysis showed consistent findings same range.